Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · IEX Real-Time Price · USD
15.09
-0.41 (-2.65%)
At close: Apr 23, 2024, 4:00 PM
15.58
+0.49 (3.25%)
After-hours: Apr 23, 2024, 7:08 PM EDT
Company Description
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases.
It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.
The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED).
The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022.
Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
Tourmaline Bio, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Dr. Sandeep C. Kulkarni M.D. |
Contact Details
Address: 27 West 24th Street, Suite 702 New York, New York 10010 United States | |
| Phone | 646-481-9832 |
| Website | tourmalinebio.com |
Stock Details
| Ticker Symbol | TRML |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001827506 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sandeep C. Kulkarni M.D. | Co-Founder, Chief Executive Officer and Director |
| Ryan Robinson CPA | Vice President of Finance, Controller and Interim Chief Financial Officer |
| Dr. Susan Dana Jones Ph.D. | Chief Technology Officer |
| W. Bradford Middlekauff J.D. | Chief Business Officer and General Counsel |
| Kimberly Piorkowski | Vice President of People, Culture and Compliance |
| Dr. Yung H. Chyung M.D. | Chief Medical Officer |
| Ryan Iarrobino | SVice President of Product Development |
| Dr. Kevin B. Johnson M.B.A., Ph.D. | Chief Regulatory Officer |
| Dora Rau | Senior Vice President and Head of Quality |
| Gerhard Hagn Pharm.D. | Senior Vice President and Head of Commercial and Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | ARS | Filing |
| Apr 19, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 19, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 19, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 19, 2024 | 10-K | Annual Report |
| Mar 19, 2024 | 8-K | Current Report |
| Mar 15, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |